Arcturus Therapeutics Stock Soars to New High Then Crashes on Trial Data – What Investors Need to Know
Arcturus stock had been riding a wave of positive sentiment through October 2025. On Oct 21 it closed at $23.16 – its highest level in a year marketbeat.com – following stronger-than-expected Q2 results. However, on Oct 22 the company’s interim cystic fibrosis data triggered a dramatic sell-off. Investing.com reported that ARCT fell about 50% as investors digested the mixed news ng.investing.com. By pre-market trading the next day it was down over 60% at roughly $9 benzinga.com. MarketBeat confirmed that Guggenheim downgraded the stock to Neutral on Oct 22 marketbeat.com. Overall, analysts remain divided: the consensus remains a “Moderate Buy” with targets around $50 marketbeat.com, but rating changes range from Zacks’ recent upgrade to “Strong Buy” to a few bearish views.